Personal Care
100 Most Popular
Health

Johnson & Johnson

$137.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.19 (-0.86%) Today
+$0.25 (0.18%) After Hours

Why Robinhood?

You can buy or sell JNJ and other stocks, options, ETFs, and crypto commission-free!

About

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. Read More The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Employees
135,100
Headquarters
New Brunswick, New Jersey
Founded
1887
Market Cap
364.50B
Price-Earnings Ratio
24.40
Dividend Yield
2.78
Average Volume
7.43M
High Today
$138.38
Low Today
$136.86
Open Price
$137.75
Volume
1.90M
52 Week High
$148.99
52 Week Low
$118.62

Collections

Personal Care
100 Most Popular
Health
Manufacturing
Retail
Healthcare
Packaging
US

News

Seeking AlphaMar 22

VA to offer J&J's Spravato to veterans with depression

The U.S. Veterans Administration (VA) has authorized its physicians to prescribe Johnson & Johnson (JNJ -0.1% ) unit Janssen Pharmaceuticals' SPRAVATO (esketamine) nasal spray for veterans with depression.

163
Seeking AlphaMar 22

J&J files European marketing application for expanded use of Darzalex

Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutica NV has filed a supplemental marketing application in Europe seeking approval to use DARZALEX (daratumumab), combined with Celgene's (NASDAQ:CELG) REVLIMID (lenalidomide) and dexamethasone, to treat multiple myeloma patients who are not candidates for high-dose chemo and autologous stem cell transplant.

18
Seeking AlphaMar 22

Johnson & Johnson bails on top candidate from $1.75B Alios Pharma buy

Johnson & Johnson (NYSE:JNJ) discloses that it will terminate development of oral RSV candidate AL-8176 that it acquired in its $1.75B acquisition of Alios Biopharma in November 2014. The company will write down the remaining $700M of the asset's intangible value this quarter. It wrote off $630M in Q3 2018....

8

Earnings

$1.72
$1.85
$1.97
$2.10
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available Apr 16, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.